Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.38 EUR | +7.60% | +14.23% | +25.70% |
Apr. 17 | OSE: licensing agreement with AbbVie enters into force | CF |
Apr. 17 | OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie | MT |
Sales 2023 | 2.23M 2.37M | Sales 2024 * | 37.83M 40.3M | Capitalization | 116M 124M |
---|---|---|---|---|---|
Net income 2023 | -23M -24.5M | Net income 2024 * | -5M -5.33M | EV / Sales 2023 | 36.2 x |
Net Debt 2023 * | 33.7M 35.9M | Net Debt 2024 * | 46.6M 49.64M | EV / Sales 2024 * | 4.3 x |
P/E ratio 2023 |
-3.63
x | P/E ratio 2024 * |
-12.5
x | Employees | 62 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 72.4% |
Latest transcript on OSE Immunotherapeutics
1 day | +7.60% | ||
1 week | +14.23% | ||
Current month | +10.70% | ||
1 month | +14.23% | ||
3 months | +44.43% | ||
6 months | +21.31% | ||
Current year | +25.70% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Nicolas Poirier
CEO | Chief Executive Officer | 42 | 16-05-30 |
Director of Finance/CFO | - | 16-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 69 | 04-11-16 | |
Director/Board Member | 66 | 23-06-21 | |
Director/Board Member | 66 | 22-02-17 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 5.38 | +7.60% | 328,456 |
24-04-18 | 5 | +2.56% | 128,837 |
24-04-17 | 4.875 | +4.84% | 248,766 |
24-04-16 | 4.65 | +0.76% | 51,090 |
24-04-15 | 4.615 | -2.02% | 46,010 |
Real-time Euronext Paris, April 19, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+25.70% | 124M | |
-1.42% | 41.52B | |
+42.15% | 39.9B | |
+1.97% | 38.83B | |
-14.19% | 26.05B | |
+1.82% | 23.78B | |
-24.55% | 18.26B | |
-4.07% | 11.65B | |
+21.36% | 11.53B | |
+8.20% | 11.2B |
- Stock Market
- Equities
- OSE Stock